RayKnowChina Research Map
Shortlist0

ShijiazhuangHebei Medical University

Fourth Hospital of Hebei Medical University

河北医科大学第四医院

Listed for 11 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Fourth Hospital of Hebei Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌123 papers led11 open trials led
  2. Hepatocellular carcinoma肝细胞癌20 papers led1 open trial led
  3. Stomach cancer胃癌104 papers led7 open trials led
  4. Hepatoblastoma肝母细胞瘤1 paper led
  5. Osteosarcoma骨肉瘤6 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤7 papers led
  7. Multiple myeloma多发性骨髓瘤4 papers led
  8. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
  9. Myasthenia gravis重症肌无力2 papers led
  10. Behçet disease白塞病0 papers led
  11. IgA nephropathyIgA 肾病1 paper led

Not listed for: Nasopharyngeal carcinoma, Retinoblastoma, Chordoma, Neuroblastoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 123 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 4.2%.

Papers led
123
2021–2025
Trials led
17
any status, ClinicalTrials.gov
Open trials led
11
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 202020212022: 313120222023: 232320232024: 202020242025: 27272025

5 hospitals in Shijiazhuang for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 13

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07266480

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  2. Recruiting
    The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07290010

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  3. Recruiting
    Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06646588

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  4. Recruiting
    Minimally Residual of Esophageal Cancer 001
    Phase
    Not given
    Started
    2023-02
    Registry
    NCT05952661

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  5. Recruiting
    Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2019-04
    Registry
    NCT03964753

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  6. Not yet recruiting
    Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07697040

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  7. Not yet recruiting
    Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07799077

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  8. Not yet recruiting
    Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07823270

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  9. Not yet recruiting
    Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06903871

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  10. Not yet recruiting
    A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07112833

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  11. Not yet recruiting
    Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06681285

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  12. Recruiting
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07700667

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  13. Recruiting
    Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT05443841

    Age not stated (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 8 listed hospitals as study sitesHefei, Nantong, Shanghai, Shijiazhuang, Taizhou (Jiangsu), Tianjin, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapyNeoadjuvant & combined treatmentMolecular markers & genomics
Departments in papersRadiation oncologyPathology / laboratory medicineMedical oncologyRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led123
  1. Exploring the Link Between Stress-Induced Naive T-Cells and Esophageal Squamous Cell Carcinoma Risk: A Multi-Omics Investigation.2026Annals of surgical oncologyFree full text
  2. The prognostic value of tumor deposits in esophageal squamous cell carcinoma: A propensity score matching study.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  3. Radiomics to predict PNI in ESCC.2025Abdominal radiology (New York)Free full text
  4. TRIM21-Mediated K11-Linked Ubiquitination of ID1 Suppresses Tumorigenesis and Promotes Cuproptosis in Esophageal Squamous Cell Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  5. The Kinesin Eg5 Inhibitor K858 Enhances Radiosensitivity in Esophageal Squamous Cell Carcinoma and Affects the Expression of Epithelial-mesenchymal Transition Related Markers: In vitro and In vivo Studies.2025Anti-cancer agents in medicinal chemistry
  6. Comparative study of neoadjuvant chemoradiotherapy, chemotherapy, and chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma.2025BMC cancerFree full text
  7. KBU2046 exerts inhibition on chemokine gradient-mediated motility of esophageal squamous cell carcinoma through reducing integrin expression.2025Biochimica et biophysica acta. Molecular basis of disease
  8. Aberrant CircTMEM45A Facilitates Inflammatory Progression of Esophageal Squamous Cell Carcinoma through m5C-Mediated NLRP3 Activation.2025Cancer research
  9. Patterns of recurrence after esophagectomy following neoadjuvant immunochemotherapy in patients with thoracic esophageal squamous cell carcinoma.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  10. The Knockdown of ACTL6A Enhances the Radiosensitivity of Esophageal Squamous Cell Carcinoma by Modulating the Wnt/β-Catenin Signaling Pathway.2025FASEB journal : official publication of the Federation of American Societies for Experimental BiologyFree full text
  11. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study.2025Frontiers in immunologyFree full text
  12. Endoplasmic reticulum stress-induced CRELD2 promotes APMAP-mediated activation of TGF-β/SMAD and NF-κB pathways in esophageal squamous cell carcinoma.2025Frontiers in immunologyFree full text
  13. Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: a multicenter, real-world, retrospective cohort study from China (NCT02025Frontiers in immunologyFree full text
  14. Nomogram-based risk stratification to analyze the value of receiving postoperative adjuvant therapy after neoadjuvant immunochemotherapy for patients with locally advanced esophageal squamous carcinoma.2025Frontiers in immunologyFree full text
  15. Serum IL-6 predicts immunotherapy-related adverse and outcome in advanced gastric and esophageal cancer patients with Anti-PD-1 treatment.2025Frontiers in immunologyFree full text
  16. Triptonide suppresses the FOXK1/AKT2 axis to reverse malignant phenotype and improve cisplatin efficacy in esophageal squamous cell carcinoma.2025Genes & genomics
  17. H-chain ferritin-based magnetic nanoparticles targeting CD71 for magnetic resonance imaging diagnosis of esophageal squamous cell carcinoma and its precancerous lesions.2025International journal of biological macromolecules
  18. CircPRKCA facilitates esophageal squamous cell carcinoma metastasis via m5C-dependent CSF2 mRNA stabilization.2025Journal of translational medicineFree full text
  19. NEK2 Promotes ESCC Malignant Progression by Inhibiting Cellular Senescence via the FOXM1/c-Myc/p27 Signaling Pathway.2025Molecular carcinogenesis
  20. Induction of CXCL8 by endoplasmic reticulum stress promotes migration and invasion of esophageal squamous cell carcinoma through activation of SMAD2/3.2025Molecular medicine reportsFree full text
  21. Targeting tumor metabolism: The dual attack of emodin on glycolysis and oxidative phosphorylation in esophageal squamous cell carcinoma.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  22. The impact of radiation-related lymphocyte recovery on the prognosis of locally advanced esophageal squamous cell carcinoma patients: a retrospective analysis.2025Radiation oncology (London, England)Free full text
  23. Real-world study of first-line immunotherapy combined with chemoradiotherapy in esophageal squamous cell carcinoma.2025Scientific reportsFree full text
  24. Prognostic value of immunotrophic inflammatory markers in ESCC undergoing chemoradiotherapy combined with immunotherapy.2025Scientific reportsFree full text
  25. The necroptosis-related lncRNA ENSG00000253385.1 promotes the progression of esophageal squamous cell carcinoma by targeting the miR-16-2-3p/VDAC1 axis.2025Scientific reportsFree full text
  26. Radiotherapy combined with chemoimmunotherapy improves survival compared to chemoimmunotherapy alone as first-line treatment for oligometastatic esophageal squamous cell carcinoma.2025Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]Free full text
  27. IFI30 Knockdown Inhibits ESCC Progression by Promoting Apoptosis and Senescence via Activation of JNK and P21/P16 Pathways.2025Thoracic cancerFree full text
  28. E2F7 promotes ESCC progression and cisplatin resistance through transcriptional activation of DVL3 and the Wnt signaling pathway.2025World journal of surgical oncologyFree full text
  29. Outcomes and predictive factors in post-surgical resection of sT4a esophageal cancer.2025World journal of surgical oncologyFree full text
  30. Computed tomography radiomics identification of T1-2 and T3-4 stages of esophageal squamous cell carcinoma: two-dimensional or three-dimensional?2024Abdominal radiology (New York)Free full text
  31. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial.2024BMC cancerFree full text
  32. Clinico-pathological study of esophageal mucoepidermoid carcinoma: a 10-year survival from a single center.2024BMC gastroenterologyFree full text
  33. Prediction of lymphovascular invasion in esophageal squamous cell carcinoma by computed tomography-based radiomics analysis: 2D or 3D ?2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  34. CircJPH1 regulates the NF-κB/HERC5 axis to promote the malignant progression of esophageal squamous cell carcinoma through binding to XRCC6.2024Cellular signalling
  35. Long Non-coding RNA X-Inactive Specific Transcript Promotes Esophageal Squamous Cell Carcinoma Progression via the MicroRNA 34a/Zinc Finger E-box-Binding Homeobox 1 Pathway.2024Digestive diseases and sciencesFree full text
  36. Clinical study of camrelizumab combined with docetaxel and carboplatin as a neoadjuvant treatment for locally advanced oesophageal squamous cell carcinoma.2024Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  37. FAM83D promotes the progression of 4NQO-induced esophageal carcinoma via inhibiting FBWX7.2024Experimental cell research
  38. SENP3 mediates the activation of the Wnt/β-catenin signaling pathway to accelerate the growth and metastasis of oesophagal squamous cell carcinoma in mice.2024Functional & integrative genomics
  39. Analysis of the incidence and mortality trends of esophageal cancer in cancer registry areas of China and Japan.2024International journal of cancer
  40. Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma.2024Journal of cancer research and clinical oncologyFree full text
  41. Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC).2024Journal of cancer research and clinical oncologyFree full text
  42. Survival benefits of adjuvant chemotherapy for patients with residual pathologic disease after neoadjuvant chemotherapy and surgery for locally advanced esophageal squamous cell carcinoma.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  43. WTAP/CCND1 axis accelerates esophageal squamous cell carcinoma progression by MAPK signaling pathway.2024Neoplasma
  44. Periplcymarin targets glycolysis and mitochondrial oxidative phosphorylation of esophageal squamous cell carcinoma: Implication in anti-cancer therapy.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  45. SNHG6 facilitates the epithelial-mesenchymal transition and metastatic potential of esophageal squamous carcinoma through miR-26b-5p/ ITGB1 axis.2024Scientific reportsFree full text
  46. Bacteroidetes promotes esophageal squamous carcinoma invasion and metastasis through LPS-mediated TLR4/Myd88/NF-κB pathway and inflammatory changes.2024Scientific reportsFree full text
  47. Treatment-related pneumonitis after thoracic radiotherapy/chemoradiotherapy combined with anti-PD-1 monoclonal antibodies in advanced esophageal squamous cell carcinoma.2024Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]Free full text
  48. LncRNA NONHSAT227443.1 Confers Esophageal Squamous Cell Carcinoma Chemotherapy Resistance by Activating PI3K/AKT Signaling via Targeting MRTFB.2024Technology in cancer research & treatmentFree full text
  49. Ethanol exposure exacerbates 4-nitroquinoline-1-oxide induced esophageal carcinogenesis and induces invasive carcinoma with muscularis propria infiltration in a mouse model.2024Toxicology and applied pharmacology
  50. Mir-25 Promotes Metastasis of Esophageal Cancer by Targeting BTG2.2023Applied biochemistry and biotechnology
  51. A novel DNA damage repair gene-related prognostic model for evaluating the prognosis and tumor microenvironment infiltration of esophageal squamous cell carcinoma.2023BMC medical genomicsFree full text
  52. CircRNA mannosidase alpha class 1A member 2 promotes esophageal squamous cell carcinoma progression by regulating C-C chemokine ligand 5.2023Biochemical and biophysical research communications
  53. Clinical Significance and Prognostic Value of the Expression of LAG-3 and FGL1 in Esophageal Squamous Cell Carcinoma.2023Bulletin of experimental biology and medicine
  54. RNA sequencing reveals the implication of the circRNA-associated ceRNA network in oesophageal squamous cell carcinoma.2023Carcinogenesis
  55. Reciprocal regulation of LINC00941 and SOX2 promotes progression of esophageal squamous cell carcinoma.2023Cell death & diseaseFree full text
  56. β-elemene Suppresses Migration of Esophageal Squamous Cell Carcinoma by Modulating Expression of MMP9 through the PI3K/Akt/NF-κB Pathway.2023Combinatorial chemistry & high throughput screening
  57. Clinical and Genomic Analysis of Patients with Short Survival after Surgery for Esophageal Squamous Cell Carcinoma.2023Digestive diseases (Basel, Switzerland)
  58. Methylation Mediated Downregulation of TOB1-AS1 and TOB1 Correlates with Malignant Progression and Poor Prognosis of Esophageal Squamous Cell Carcinoma.2023Digestive diseases and sciences
  59. Potential 'anti-cancer' effects of esketamine on proliferation, apoptosis, migration and invasion in esophageal squamous carcinoma cells.2023European journal of medical researchFree full text
  60. Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospectiv2023Frontiers in immunologyFree full text
  61. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.2023Frontiers in immunologyFree full text
  62. P-Hydroxylcinnamaldehyde induces tumor-associated macrophage polarization toward the M1 type by regulating the proteome and inhibits ESCC in vivo and in vitro.2023International immunopharmacology
  63. Comparison of TNM AJCC/UICC 8th with JES 11th staging systems for prognostic prediction in patients with esophageal squamous cell carcinoma who underwent radical (chemo) radiotherapy in China.2023Journal of cancer research and therapeutics
  64. Circular RNA circ-TNRC6B inhibits the proliferation and invasion of esophageal squamous cell carcinoma cells by regulating the miR-452-5p/DAG1 axis.2023Molecular oncologyFree full text
  65. Circular RNA hsa_circ_0002938 (circCRIM1) promotes the progression of esophageal squamous cell carcinoma by upregulating transcription factor 12.2023Neoplasma
  66. Aprepitant inhibits the progression of esophageal squamous cancer by blocking the truncated neurokinin‑1 receptor.2023Oncology reportsFree full text
  67. The host microbiota is associated with the occurrence and development of esophageal squamous cell carcinoma.2023Protein & cellFree full text
  68. Elective nodal irradiation versus involved-field irradiation for stage II-IV cervical esophageal squamous cell carcinoma patients undergoing definitive concurrent chemoradiotherapy: a retrospective propensity study with 8-year survival outc2023Radiation oncology (London, England)Free full text
  69. FOXK1 regulates malignant progression and radiosensitivity through direct transcriptional activation of CDC25A and CDK4 in esophageal squamous cell carcinoma.2023Scientific reportsFree full text
  70. Effect of extracapsular lymph node involvement on the prognosis of patients with esophageal squamous cell carcinoma.2023Technology and health care : official journal of the European Society for Engineering and Medicine
  71. Tracheoesophageal fistula closure after staged dose-escalated radiotherapy for esophageal squamous cell carcinoma: a case report.2023The Journal of international medical researchFree full text
  72. Bioinformatics and network pharmacology identify promotional effects and potential mechanisms of ethanol on esophageal squamous cell carcinoma and experimental validation.2023Toxicology and applied pharmacology
  73. MicroRNA-181a-5p prevents the progression of esophageal squamous cell carcinoma in vivo and in vitro via the MEK1-mediated ERK-MMP signaling pathway.2022AgingFree full text
  74. MDM4 polymorphisms associated with the risk but not the prognosis of esophageal cancer in Cixian high-incidence region from northern China.2022Asia-Pacific journal of clinical oncology
  75. Development and validation of a nomogram for prediction of cervical lymph node metastasis in middle and lower thoracic esophageal squamous cell carcinoma.2022BMC gastroenterologyFree full text
  76. Can lymphovascular invasion be predicted by contrast-enhanced CT imaging features in patients with esophageal squamous cell carcinoma? A preliminary retrospective study.2022BMC medical imagingFree full text
  77. ESM1 Is a Promising Therapeutic Target and Prognostic Indicator for Esophageal Carcinogenesis/Esophageal Squamous Cell Carcinoma.2022BioMed research internationalFree full text
  78. Apatinib Combined with Paclitaxel and Cisplatin Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.2022Cancer biotherapy & radiopharmaceuticalsRCT
  79. SNHG17, as an EMT-related lncRNA, promotes the expression of c-Myc by binding to c-Jun in esophageal squamous cell carcinoma.2022Cancer scienceFree full text
  80. Long non-coding RNA NRSN2-AS1, transcribed by SOX2, promotes progression of esophageal squamous cell carcinoma by regulating the ubiquitin-degradation of PGK1.2022Clinical & experimental metastasis
  81. Downregulation of LINC00886 facilitates epithelial-mesenchymal transition through SIRT7/ELF3/miR-144 pathway in esophageal squamous cell carcinoma.2022Clinical & experimental metastasis
  82. Folate Receptor 4-Expressing T cell Is Associated with Disease-Free Survival in Patients with Esophageal Squamous Cell Carcinoma.2022Disease markersFree full text
  83. Baicalein Inhibits the Progression and Promotes Radiosensitivity of Esophageal Squamous Cell Carcinoma by Targeting HIF-1A.2022Drug design, development and therapyFree full text
  84. LncRNA GATA2-AS1 suppresses esophageal squamous cell carcinoma progression via the mir-940/PTPN12 axis.2022Experimental cell research
  85. CAF-derived exosomes deliver LINC01410 to promote epithelial-mesenchymal transition of esophageal squamous cell carcinoma.2022Experimental cell research
  86. The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma.2022Frontiers in immunologyFree full text
  87. Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching.2022Frontiers in immunologyFree full text
  88. Case Report: Immune Checkpoint Inhibitors Successfully Controlled Asymptomatic Brain Metastasis in Esophageal Squamous Cell Carcinoma.2022Frontiers in immunologyFree full text
  89. Irradiation-induced exosomal HMGB1 to confer radioresistance via the PI3K/AKT/FOXO3A signaling pathway in ESCC.2022Journal of translational medicineFree full text
  90. Recent advances in esophageal squamous cell precancerous conditions: A review.2022MedicineFree full text
  91. Novel nomograms predicting the survival of patients with nonsurgical thoracic esophageal squamous cell carcinoma treated with IMRT: A retrospective analysis.2022MedicineFree full text
  92. HMGB1 induces radioresistance through PI3K/AKT/ATM pathway in esophageal squamous cell carcinoma.2022Molecular biology reportsFree full text
  93. Roles of PTEN inactivation and PD-1/PD-L1 activation in esophageal squamous cell carcinoma.2022Molecular biology reports
  94. circCYP24A1 facilitates esophageal squamous cell carcinoma progression through binding PKM2 to regulate NF-κB-induced CCL5 secretion.2022Molecular cancerFree full text
  95. Prognostic Significance of Prognostic Nutritional Index in Esophageal Squamous Cell Carcinoma Patients Undergoing Radical Radiotherapy: A Propensity Score Matching Analysis.2022Nutrition and cancer
  96. E2F1-activated NRSN2 promotes esophageal squamous cell carcinoma progression through AKT/mTOR pathway.2022Pathology, research and practice
  97. KTN1-AS1, a SOX2-mediated lncRNA, activates epithelial-mesenchymal transition process in esophageal squamous cell carcinoma.2022Scientific reportsFree full text
  98. The circRNA circADAMTS6 promotes progression of ESCC and correlates with prognosis.2022Scientific reportsFree full text
  99. Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and standard-dose intensity-modulated radiotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study.2022Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]Free full text
  100. Effect of taking aspirin before diagnosis on the prognosis of esophageal squamous cell carcinoma and analysis of prognostic factors.2022The Journal of international medical researchFree full text
  101. Is adjuvant immunotherapy a new standard for non-pathological complete response patients with resectable esophageal squamous cell carcinoma?2022Thoracic cancerFree full text
  102. Circ_0005231 promotes the progression of esophageal squamous cell carcinoma via sponging miR-383-5p and regulating KIAA0101.2022Thoracic cancerFree full text
  103. Could intracranial tumor volume predict prognosis of patients with brain metastases from esophageal carcinoma?2022Thoracic cancerFree full text
  104. Preliminary analysis of the benefits of different irradiation types on patients with postoperative locoregional recurrence of esophageal cell squamous carcinoma.2021Annals of palliative medicine
  105. Postoperative Adjuvant Therapy for Patients with pN+ Esophageal Squamous Cell Carcinoma.2021BioMed research internationalFree full text
  106. LncRNA DDX11 antisense RNA 1 promotes EMT process of esophageal squamous cell carcinoma by sponging miR-30d-5p to regulate SNAI1/ZEB2 expression and Wnt/β-catenin pathway.2021BioengineeredFree full text
  107. CDH1 Gene rs1801552 C/T Polymorphism Increases Susceptibility to Esophageal Squamous Cell Carcinoma but Not to Gastric Cardiac Adenocarcinoma.2021Cancer investigation
  108. ZEB1 represses biogenesis of circ-DOCK5 to facilitate metastasis in esophageal squamous cell carcinoma via a positive feedback loop with TGF-β.2021Cancer letters
  109. MTA2 promotes the metastasis of esophageal squamous cell carcinoma via EIF4E-Twist feedback loop.2021Cancer scienceFree full text
  110. SNHG5 inhibits the progression of EMT through the ubiquitin-degradation of MTA2 in oesophageal cancer.2021Carcinogenesis
  111. Long noncoding RNA DGCR5 involves in tumorigenesis of esophageal squamous cell carcinoma via SRSF1-mediated alternative splicing of Mcl-1.2021Cell death & diseaseFree full text
  112. Gene mutations of esophageal squamous cell carcinoma based on next-generation sequencing.2021Chinese medical journalFree full text
  113. TIM-3 polymorphism is involved in the progression of esophageal squamous cell carcinoma by regulating gene expression.2021Environmental and molecular mutagenesis
  114. HNRNPUL1 inhibits cisplatin sensitivity of esophageal squamous cell carcinoma through regulating the formation of circMAN1A2.2021Experimental cell research
  115. SNORA42 promotes oesophageal squamous cell carcinoma development through triggering the DHX9/p65 axis.2021Genomics
  116. Survival risk prediction model for patients with pT1-3 N0M0 esophageal squamous cell carcinoma after R0 esophagectomy with two-field lymphadenectomy for therapeutic purposes.2021Journal of cardiothoracic surgeryFree full text
  117. Long non-coding RNA SPRY4-IT1 as a promising indicator for three field lymph-node dissection of thoracic esophageal carcinoma.2021Journal of cardiothoracic surgeryFree full text
  118. Effects of preoperative radiotherapy on survival of patients with stage II and III esophageal squamous cell carcinoma: A population-based study.2021MedicineFree full text
  119. Long non-coding RNA NORAD/miR-224-3p/MTDH axis contributes to CDDP resistance of esophageal squamous cell carcinoma by promoting nuclear accumulation of β-catenin.2021Molecular cancerFree full text
  120. LINC00239 Interacts with C-Myc Promoter-Binding Protein-1 (MBP-1) to Promote Expression of C-Myc in Esophageal Squamous Cell Carcinoma.2021Molecular cancer research : MCR
  121. FOXD3 suppresses epithelial-mesenchymal transition through direct transcriptional promotion of SMAD7 in esophageal squamous cell carcinoma.2021Molecular carcinogenesis
  122. MicroRNA‑485‑5p suppresses the progression of esophageal squamous cell carcinoma by targeting flotillin‑1 and inhibits the epithelial‑mesenchymal transition.2021Oncology reportsFree full text
  123. MicroRNA-29b regulates the radiosensitivity of esophageal squamous cell carcinoma by regulating the BTG2-mediated cell cycle.2021Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
Chinese-language papers (not in the count)4
  1. [LINC00261 suppresses esophageal squamous cell carcinoma proliferation, invasion, and metastasis by targeting the miR-23a-3p/ZNF292 axis].2025Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  2. [Efficacy and safety of immunotherapy combined with chemotherapy as conversion therapy for initially unresectable locally advanced esophageal squamous cell carcinoma].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  3. [MiR-1-3p inhibits mitophagy in esophageal squamous cell carcinoma by targeting SLC7A11].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
  4. [Prognostic analysis of different comprehensive treatment models for locally advanced esophageal squamous cell carcinoma based on propensity score matching].2022Zhonghua wai ke za zhi [Chinese journal of surgery]
All its trials on ClinicalTrials.gov, any status24
  1. Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCCNot yet recruitingNCT07697040Lead sponsorPhase 1Start 2026-07
  2. Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07823270Lead sponsorPhase 2Start 2026-10
  3. Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07799077Lead sponsorPhase 2Start 2026-09
  4. Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)Not yet recruitingNCT06903871Lead sponsorPhase 2Start 2025-04
  5. Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.RecruitingNCT07266480Lead sponsorPhase 2Start 2025-09
  6. A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)Not yet recruitingNCT07112833Lead sponsorPhase 2Start 2025-08
  7. The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell CarcinomaRecruitingNCT07290010Lead sponsorPhase 2Start 2025-09
  8. Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell CarcinomaRecruitingNCT06646588Lead sponsorPhase 2Start 2024-04
  9. Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)Not yet recruitingNCT06681285Lead sponsorPhase 2Start 2024-11
  10. Minimally Residual of Esophageal Cancer 001RecruitingNCT05952661Lead sponsorStart 2023-02
  11. Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT03964753Lead sponsorPhase 2Start 2019-04
  12. Dynamic ctDNA Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell CarcinomaStatus unknownNCT06103890Lead sponsorStart 2023-05
  13. A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCCStatus unknownNCT04286958Lead sponsorPhase 2Start 2020-04
  14. Clinical Research on the Effect of Aspirin on the Disease Free Survival Rate of Esophageal CarcinomaStatus unknownNCT03900871Lead sponsorEarly phase 1Start 2019-04
  15. Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma(ChinECR)Status unknownNCT06478355Lead sponsorN/AStart 2018-01
  16. A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell CarcinomaTerminatedNCT03320629Lead sponsorPhase 2Start 2017-11
  17. The Neoadjuvant Treatment Modalities in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (NEO-EC)Active, not recruitingNCT06828718Lead sponsorStart 2015-01
  18. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  19. Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)RecruitingNCT05443841Study siteStart 2022-07
  20. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.CompletedNCT05142709Study siteStart 2021-10
  21. Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell CarcinomaCompletedNCT04974047Study sitePhase 2Start 2021-08
  22. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  23. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedNCT04543617Study sitePhase 3Start 2020-09
  24. A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell CarcinomaStatus unknownNCT02409186Study sitePhase 3Start 2015-03
More papers found outside PubMed (not counted)57
  1. 152. THE PROGNOSTIC IMPACT OF PARA-RECURRENT LARYNGEAL NERVE LYMPH NODE DISSECTION IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A RETROSPECTIVE COHORT STUDY2025Diseases of the Esophagusarticle
  2. 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  3. 233eTiP Adebrelimab in the adjuvant treatment of esophageal squamous cell carcinoma: A randomized controlled clinical trial (PAIT-ESCC-0825)2025Immuno-Oncology Technologyarticle
  4. 349. PATHOLOGIC COMPLETE RESPONSE IN ESOPHAGEAL SQUAMOUS CELL CANCER: DO DIVERSE NEOADJUVANT MODALITIES PREDICT PROGNOSTIC DIFFERENCES?2025Diseases of the Esophagusarticle
  5. Abstract 1945: High-sensitive gastrointestinal cancers early detection by cell-free DNA targeted methylation sequencing with an innovative modeling approach2025Cancer Researchconference-abstract
  6. Analysis of Treatment Patterns and Prognostic Factors in Patients with Esophageal Fistula after Radiotherapy for Esophageal Squamous Cell Carcinoma2025International Journal of Radiation Oncology*Biology*Physicsarticle
  7. Consolidative camrelizumab following definitive concurrent chemoradiotherapy with involved-field irradiation in locally advanced esophageal squamous cell carcinoma: A single-arm phase 2 trial.2025Journal of Clinical Oncologyconference-abstract
  8. Effect of fusobacterium nucleatum on NF-κB/HIF-1α/CCL20 pathway and M2 macrophages infiltration in esophageal squamous cell carcinoma.2025Journal of Clinical Oncologyconference-abstract
  9. Efficacy and Safety of Neoadjuvant Therapies in Locally Advanced Esophageal Squamous Cell Carcinoma: A Comprehensive Retrospective Analysis2025International Journal of Radiation Oncology*Biology*Physicsarticle
  10. Perioperative adebrelimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: A single-arm, open-label, multicenter study.2025Journal of Clinical Oncologyconference-abstract
  11. Potential role of CCND1 in neoadjuvant therapy efficacy in esophageal squamous cell carcinoma and its relation to extracellular matrix.2025Journal of Clinical Oncologyarticle
  12. Regulation of tumor-associated fibroblasts by TACSTD2 in esophageal squamous cell carcinoma and its potential role in immunotherapy resistance.2025Journal of Clinical Oncologyarticle
  13. Study on DLGAP5 and MELK as potential biomarkers in esophageal squamous cell carcinoma2025Research Squarepreprint
  14. Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis2025Journal of Clinical Oncologyconference-abstract
  15. WITHDRAWN: 2143P Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: A multicenter, real-world, retrospective cohort study2025Annals of Oncologyretraction
  16. A zinc oxide–tin oxide–nerolidol hybrid nanomaterial: Efficacy against esophageal squamous cell carcinoma2024Open Chemistryarticle
  17. Efficacy and Safety of Radiotherapy Combined with Chemoimmunotherapy vs. Chemoimmunotherapy Alone as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma with Oligorecurrence2024International Journal of Radiation Oncology*Biology*Physicsarticle
  18. FOXD1 promotes proliferation, migration, and epithelial-mesenchymal transformation in esophageal squamous cell carcinoma by targeting SNAI12024Process Biochemistryarticle
  19. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncologyconference-abstract
  20. Fusobacterium nucleatum to promote esophageal squamous cell carcinoma progression via CCL20/CCR6-mediated migration of macrophages to the tumour micro environment.2024Journal of Clinical Oncologyconference-abstract
  21. Pathological Response and Survival Outcome after Neoadjuvant Chemoradiotherapy vs. Immunochemotherapy for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma2024International Journal of Radiation Oncology*Biology*Physicsarticle
  22. Patterns of recurrence after esophagectomy following neoadjuvant Immunochemotherapy for esophageal squamous cell carcinoma.2024Journal of Clinical Oncologyconference-abstract
  23. Radiotherapy Combined with Chemoimmunotherapy vs. Chemoimmunotherapy Alone as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma with Oligometastasis at Initial Diagnosis2024International Journal of Radiation Oncology*Biology*Physicsarticle
  24. The clinical significance and expression of MAGE-A3 in patients with esophageal squamous cell carcinoma.2024Journal of Clinical Oncologyconference-abstract
  25. The clinical significance of PRMT8 expression in esophageal squamous cell carcinoma and the influence on prognosis.2024Journal of Clinical Oncologyconference-abstract
  26. Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: A multicenter, randomized, parallel-controlled, phase II clinical t2024Journal of Clinical Oncologyconference-abstract
  27. Tumor Immune Microenvironment Remodeling and Prognosis of Patients with Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy with and without Immunotherapy2024International Journal of Radiation Oncology*Biology*Physicsarticle
  28. 145P Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)2023Annals of Oncologyarticle
  29. 1573P Involved field and elective nodal irradiation presented similar treatment efficiency in concurrent chemoradiation for locally advanced ESCC2023Annals of Oncologyarticle
  30. Elective Nodal Irradiation vs. Involved-Field Irradiation for Stage Ⅱ-Ⅳ Cervical Esophageal Squamous Cell Carcinoma Patients Undergoing Definitive Concurrent Chemoradiotherapy: A Retrospective Propensity Study with Eight-Year Survival Outco2023International Journal of Radiation Oncology*Biology*Physicsarticle
  31. Meta-analysis of the efficacy and toxicity of paclitaxel combined with platinum (PTX) and fluorouracil combined with cisplatin (PF) in the treatment of concurrent chemoradiotherapy (CCRT) for unresectable esophageal cancer2023Research Squarepreprint
  32. SF3B4 Regulated Alternative Splicing that Produced an Oncogenic Isoform of HOXA11-AS to Promote Glycolytic Reprogramming and ESCC Progression2023Research Squarepreprint
  33. The efficacy and safety of neoadjuvant sintilimab combined with chemotherapy in elderly patients with locally advanced esophageal squamous cell carcinoma.2023Journal of Clinical Oncologyconference-abstract
  34. 1207P Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study2022Annals of Oncologyarticle
  35. 1234P Neoadjuvant camrelizumab plus docetaxel and carboplatin in locally advanced esophageal squamous cell carcinoma (ESCC): A prospective study2022Annals of Oncologyarticle
  36. 1262TiP Efficacy and safety of consolidative camrelizumab following definitive concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell cancer2022Annals of Oncologyarticle
  37. A randomized, controlled, multicenter study of nab-paclitaxel plus cisplatin followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma (ESCC).2022Journal of Clinical Oncologyconference-abstract
  38. Additional file 1 of Development and validation of a nomogram for prediction of cervical lymph node metastasis in middle and lower thoracic esophageal squamous cell carcinoma2022Figsharedataset
  39. Concurrent Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and Different Target Field (ENI vs. IFI) for Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Randomized, Multicenter Phase Ⅲ Clinical Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  40. Expression of FGL1, Distribution of Tumor-Infiltrating Lymphocytes, and Their Clinical Significance in Esophageal Squamous-Cell Carcinoma2022DOAJ (DOAJ: Directory of Open Access Journals)article
  41. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncologyconference-abstract
  42. Risk Factors of Treatment-Related Pneumonitis after Thoracic Radiotherapy/Chemoradiotherapy Combined with Anti-PD-1 mAb in Esophageal Squamous Cell Carcinoma2022International Journal of Radiation Oncology*Biology*Physicsarticle
  43. SRSF1 promotes proliferation, invasion and migration of esophageal squamous cell carcinoma Eca9706 cells by regulating VEGFA mRNA alternative splicing2022DOAJ (DOAJ: Directory of Open Access Journals)article
  44. The microbial characteristics of patients with esophageal squamous cell carcinoma after chemotherapy and after immunotherapy.2022Journal of Clinical Oncologyconference-abstract
  45. 110P Neoadjuvant PD-1 blockade combined with chemotherapy for patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC): A real world data analysis2021Annals of Oncologyarticle
  46. 155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm pha2021Annals of Oncologyarticle
  47. 557 Neoadjuvant Camrelizumab in combination with albumin paclitaxel and cisplatin for patients with locally advanced esophageal squamous cell carcinoma (ESCC)2021Journal for ImmunoTherapy of Cancerconference-abstract
  48. 978P A prospective study of camrelizumab monotherapy following definitive concurrent chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell cancer2021Annals of Oncologyarticle
  49. A Nomogram Model Based on Enhanced CT Radiomics Features for Predicting Tumor Response to Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma2021Research Squarepreprint
  50. Addition of Induction or Consolidation Chemotherapy in Definitive Concurrent Chemoradiotherapy vs. Concurrent Chemoradiotherapy Alone for Patients With Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis2021International Journal of Radiation Oncology*Biology*Physicsarticle
  51. Camrelizumab combined with albumin paclitaxel and cisplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract
  52. Corrigendum: Contrast-Enhanced CT-Based Radiomics Analysis in Predicting Lymphovascular Invasion in Esophageal Squamous Cell Carcinoma2021Frontiers in Oncologyerratum
  53. Exosome Releasing HSPD1 Assists HNF1A in Regulating the Invasion Ability and Radiosensitivity of Esophageal Squamous Cell Carcinoma Cells via Activating EMT2021Research Squarepreprint
  54. Expression of LncRNA DLEU1 in Esophageal Squamous Cell Carcinoma and Its Effect on Proliferation and Migration of ESCC Cells2021DOAJ (DOAJ: Directory of Open Access Journals)article
  55. Impact and Analysis of Prognostic Factors in Patients with Non-Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Single Institution Study2021Open Journal of Internal Medicinearticle
  56. Radiotherapy for Esophageal Squamous Cell Carcinoma Concomitant With Hypoproteinemia: a Case Report2021Venue not listedpreprint
  57. The microbial characteristics of patients with esophageal squamous cell carcinoma before and after immunotherapy.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 20 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
20
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 3320212022: 6620222023: 3320232024: 3320242025: 552025

4 hospitals in Shijiazhuang for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT07179900

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  2. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  3. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsLocal treatment (ablation, TACE, HAIC)
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRheumatology & immunologyMedical oncology
Papers it led20
  1. Estrogen receptor α suppresses hepatocellular carcinoma by restricting M2 macrophage infiltration through the YAP-CCL2 axis.2025BMC cancerFree full text
  2. Identification and validation of a lenvatinib resistance-related prognostic signature in HCC, in which PFKFB4 contributes to tumor progression and lenvatinib resistance.2025BMC gastroenterologyFree full text
  3. Role of CD28+ PD-1+ Tc cells in immune response and prognosis prediction in hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  4. CD161, a promising prognostic biomarker in hepatocellular carcinoma, correlates with immune infiltration.2025PeerJFree full text
  5. Hypoxia-activated oxidative stress mediates SHP2/PI3K signaling pathway to promote hepatocellular carcinoma growth and metastasis.2025Scientific reportsFree full text
  6. G-CSF promotes the development of hepatocellular carcinoma by activating the PI3K/AKT/mTOR pathway in TAM.2024AgingFree full text
  7. Prediction of survival and analysis of prognostic factors for patients with AFP negative hepatocellular carcinoma: a population-based study.2024BMC gastroenterologyFree full text
  8. The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients.2024Frontiers in immunologyFree full text
  9. Role of TOP2A and CDC6 in liver cancer.2023MedicineFree full text
  10. Molecular docking and in vitro experiments verified that kaempferol induced apoptosis and inhibited human HepG2 cell proliferation by targeting BAX, CDK1, and JUN.2023Molecular and cellular biochemistry
  11. Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.2023Technology in cancer research & treatmentFree full text
  12. An asparagine metabolism-based classification reveals the metabolic and immune heterogeneity of hepatocellular carcinoma.2022BMC medical genomicsFree full text
  13. GCSF as a Potential Molecular Target for Overall Survival of Hepatocellular Carcinoma.2022Combinatorial chemistry & high throughput screening
  14. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.2022Frontiers in endocrinologyFree full text
  15. Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index.2022Future oncology (London, England)
  16. PRR34-AS1 promotes exosome secretion of VEGF and TGF-β via recruiting DDX3X to stabilize Rab27a mRNA in hepatocellular carcinoma.2022Journal of translational medicineFree full text
  17. Up-Frameshift Suppressor 3 as a prognostic biomarker and correlated with immune infiltrates: A pan-cancer analysis.2022PloS oneFree full text
  18. Hydrazinocurcumin Induces Apoptosis of Hepatocellular Carcinoma Cells Through the p38 MAPK Pathway.2021Clinical and translational scienceFree full text
  19. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.2021Frontiers in immunologyFree full text
  20. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.2021Recent patents on anti-cancer drug discovery
Chinese-language papers (not in the count)1
  1. [HDAC2-mediated H3K27 acetylation promotes the proliferation and migration of hepatocellular carcinoma cells].2025Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciencesFree full text
All its trials on ClinicalTrials.gov, any status5
  1. Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular CarcinomaRecruitingNCT07179900Lead sponsorPhase 2Start 2025-03
  2. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  3. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  4. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  5. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma SubjectsStatus unknownNCT03236636Study sitePhase 3Start 2017-09

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 104 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.1%.

Papers led
104
2021–2025
Trials led
17
any status, ClinicalTrials.gov
Open trials led
7
recruiting or about to
Open trials as a site
11
led by another institution
Papers led per year
2021: 202020212022: 151520222023: 191920232024: 262620242025: 23232025

5 hospitals in Shijiazhuang for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 18

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    DeepComp for Prediction of Gastric Cancer Postoperative Complications (DeepComp-Prospective)
    Phase
    Not given
    Started
    2026-03
    Registry
    NCT07401173

    Age 18 years to 85 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  2. Recruiting
    Silent Evaluation of DeepTRG for Assessing Tumor Response After Preoperative Treatment in Stomach and Gastroesophageal Junction Cancer
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07849608

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  3. Recruiting
    Multimodal Deep Learning for Lymph Node Metastasis Prediction and Physician Performance Assessment in T1 Gastric Cancer
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT07124754

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  4. Recruiting
    Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07289997

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  5. Not yet recruiting
    A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07304258

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  6. Enrolling by invitation
    Radiomics-Based AI Model for Predicting Para-Aortic Lymph Node Metastasis in Gastric Cancer Patients
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT06947096

    Age 18 years to 80 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  7. Enrolling by invitation
    AI-Based Prediction of Lymph Node Metastasis in Gastric Cancer Using Preoperative Multimodal Data
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT06957678

    Age 18 years to 80 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  8. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  9. Recruiting
    Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
    Phase
    Not given
    Started
    2026-02
    Registry
    NCT07401199

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShijiazhuang, Wuhan

  10. Recruiting
    Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07552402

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Nanning, Shanghai, Shijiazhuang, Suzhou, Wuhan, Yinchuan

  11. Recruiting
    A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-08
    Registry
    NCT07023315

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Harbin, Shanghai, Shijiazhuang

  12. Recruiting
    A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07110571

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Shijiazhuang

  13. Recruiting
    Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07127822

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Harbin, Qingdao, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  14. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  15. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  16. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  17. Not yet recruiting
    Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07828899

    Age 18 years to 85 years (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical University; 2 listed hospitals as study sitesJinan, Shijiazhuang, Wenzhou

  18. Not yet recruiting
    Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07902596

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 6 listed hospitals as study sitesNanjing, Qingdao, Shanghai, Shijiazhuang, Suzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseImaging & AISurgery
Departments in papersGastroenterology / hepatologyRheumatology & immunologyRadiology / nuclear medicineMedical oncology
Papers it led104
  1. Safety and feasibility of robot-assisted remote radical gastrectomy for gastric cancer based on 5G communication technology (FUTURE-04): a prospective, single-arm clinical trial.2026Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  2. Interpretable Multimodal Fusion Model Enhances Postoperative Recurrence Prediction in Gastric Cancer.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. Multimodal Artificial Intelligence-Based Virtual Biopsy for Diagnosing Abdominal Lavage Cytology-Positive Gastric Cancer.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  4. Diagnostic value of the cardiophrenic lymph nodes in gastric peritoneum metastases.2025African health sciencesFree full text
  5. Safety and short‑term outcomes of a modified tubular esophagogastrostomy versus double tract reconstruction after proximal gastrectomy: a propensity score matching analysis.2025BMC cancerFree full text
  6. Association of low skeletal muscle mass and radiodensity with clinical outcomes in patients undergoing robotic radical gastric cancer surgery: a population-based retrospective cohort study.2025BMC cancerFree full text
  7. Preoperative sarcopenia and postoperative accelerated muscle loss negatively impact survival after resection of locally advanced gastric cancer.2025BMC cancerFree full text
  8. Radiomics-based ensemble model predicts postoperative recurrence of gastric cancer.2025BMC medicineFree full text
  9. Safety and efficacy of the Toumai robotic assisted versus the DaVinci robotic assisted radical gastrectomy for patients with gastric cancer.2025BMC surgeryFree full text
  10. Comparative clinical efficacy of hybrid EMR-hot avulsion versus thermal ablation for post-ESD residual margins (≤ 1 cm) in early gastric cancer: a preliminary study.2025BMC surgeryFree full text
  11. SphK2 promotes the progression of Helicobacter pylori-positive gastric cancer by regulating the Ras/MEK/ERK pathway.2025Biochemical and biophysical research communications
  12. Identification of Anoikis-Related Genes in Gastric Cancer: Bioinformatics and Experimental Validation.2025Cancer medicineFree full text
  13. Immunohistochemical-Based Molecular Typing of ACRG Combined With Immune-Associated PD-L1 Expression Can Predict the Prognosis of Gastric Cancer.2025Cancer medicineFree full text
  14. Huopuxialing Decoction: A Promising Candidate for Precancerous Lesions of Gastric Cancer Treatment Based on Bioinformatics and Experimental Verification.2025Combinatorial chemistry & high throughput screening
  15. Concomitant gastric cancer and neuroendocrine tumours in the stomach: a rare case series of 3 patients and a literature review.2025Diagnostic pathologyFree full text
  16. Subcutaneous adipose tissue [18F]FDG uptake and CT-derived body composition variables for predicting survival outcomes in patients with locally advanced gastric cancer.2025European journal of nuclear medicine and molecular imaging
  17. Efficacy of traditional Chinese medicine in the conservative management of complete small intestinal obstruction post-gastric cancer surgery: A case report.2025Explore (New York, N.Y.)
  18. Serum IL-6 predicts immunotherapy-related adverse and outcome in advanced gastric and esophageal cancer patients with Anti-PD-1 treatment.2025Frontiers in immunologyFree full text
  19. Preoperative liquid biopsy transcriptomic panel for risk assessment of lymph node metastasis in T1 gastric cancer.2025Journal of experimental & clinical cancer research : CRFree full text
  20. Lymph node metastasis mapping and prognostic analysis of early gastric cancer.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  21. Comparative genomic analysis unveiling the mutational landscape associated with premalignant lesions and early-stage gastric cardia cancer.2025MedicineFree full text
  22. Huo Po Xia Ling decoction exerts preventive and improvement effects on gastric precancerous lesions by remodeling gut microbiota and associated metabolites.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  23. Lian Qiao Wen Dan Decoction attenuates gastric carcinogenesis by alleviating oxidative phosphorylation dysfunction.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  24. FDP/FIB ratio serves as a novel biomarker for diagnosing bone marrow invasion in gastric cancer and predicting patient prognosis\.2025Scientific reportsFree full text
  25. Deep learning nomogram for predicting neoadjuvant chemotherapy response in locally advanced gastric cancer patients.2024Abdominal radiology (New York)Free full text
  26. Clinical calculator based on CT and clinicopathologic characteristics predicts short-term prognosis following resection of microsatellite-stabilized diffuse gastric cancer.2024Abdominal radiology (New York)
  27. Transcriptomics-Based Liquid Biopsy for Early Detection of Recurrence in Locally Advanced Gastric Cancer.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  28. LncRNA HAGLR regulates gastric cancer progression by regulating the miR-20a-5p/E2F1 axis.2024AgingFree full text
  29. Endoscopic submucosal dissection in a patient with gastric submucosal parasitic granuloma.2024Asian journal of surgery
  30. Continuation of same programmed death-1 inhibitor regime beyond progression is a novel option for advanced gastric cancer.2024BMC cancerFree full text
  31. Combined systemic inflammatory immune index and prognostic nutrition index as chemosensitivity and prognostic markers for locally advanced gastric cancer receiving neoadjuvant chemotherapy: a retrospective study.2024BMC cancerFree full text
  32. Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients.2024BMC cancerFree full text
  33. Blood lipid profiles associated with metastatic sites in advanced gastric cancer.2024BMC gastroenterologyFree full text
  34. Mapping spatial heterogeneity in gastric cancer microenvironment.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  35. Application of Intelligent Management Model Based on Electronic Patient-Reported Outcome During Immunotherapy in Patients with Gastric Cancer: A Single-Center Retrospective Study.2024British journal of hospital medicine (London, England : 2005)
  36. Effect of Personalized Nutrition Combined with Acceptance and Commitment Therapy on Psychological Resilience, Quality of Life and Side Effects of Chemotherapy in Patients with Advanced Gastric Cancer.2024British journal of hospital medicine (London, England : 2005)
  37. Noninvasive Assessment of HER2 Expression Status in Gastric Cancer Using 18F-FDG Positron Emission Tomography/Computed Tomography-Based Radiomics: A Pilot Study.2024Cancer biotherapy & radiopharmaceuticals
  38. BBOX1-AS1 promotes gastric cardia adenocarcinoma progression via interaction with CtBP2 to facilitate the epithelial-mesenchymal transition process.2024Cancer scienceFree full text
  39. Exploring the Pharmacological Mechanisms of P-hydroxylcinnamaldehyde for Treating Gastric Cancer: A Pharmacological Perspective with Experimental Confirmation.2024Current molecular pharmacology
  40. Myosteatosis predicts postoperative complications and long-term survival in robotic gastrectomy for gastric cancer: A propensity score analysis.2024European journal of clinical investigation
  41. The impact of immune-related adverse events on the outcome of advanced gastric cancer patients with immune checkpoint inhibitor treatment.2024Frontiers in immunologyFree full text
  42. A retrospective analysis of lymph node dissection in Siewert II adenocarcinoma of the esophagogastric junction.2024Journal of cardiothoracic surgeryFree full text
  43. Transcriptomics-based liquid biopsy panel for early non-invasive identification of peritoneal recurrence and micrometastasis in locally advanced gastric cancer.2024Journal of experimental & clinical cancer research : CRFree full text
  44. Circ_0001947 encapsulated by small extracellular vesicles promotes gastric cancer progression and anti-PD-1 resistance by modulating CD8+ T cell exhaustion.2024Journal of nanobiotechnologyFree full text
  45. MicroRNA-431-5p inhibits angiogenesis, lymphangiogenesis, and lymph node metastasis by affecting TGF-β1/SMAD2/3 signaling via ZEB1 in gastric cancer.2024Molecular carcinogenesis
  46. Comparison of 68 Ga-FAPI-04 PET/CT with 18 F-FDG PET/CT for diagnosis and staging of gastric and colorectal cancer.2024Nuclear medicine communications
  47. Impact of preoperative sarcopenia on postoperative complications and prognosis in patients undergoing robotic gastric cancer surgery: A propensity score matching study.2024Nutrition (Burbank, Los Angeles County, Calif.)
  48. N6-methyladenosine modified circPAK2 promotes lymph node metastasis via targeting IGF2BPs/VEGFA signaling in gastric cancer.2024Oncogene
  49. Data-independent acquisition combined with liquid chromatography mass spectrometry technique to detect prognostic protein markers in type I gastric neuroendocrine neoplasm.2024Rapid communications in mass spectrometry : RCM
  50. Gastric metastasis from breast cancer: five cases and a single-institutional review.2024The Journal of international medical researchFree full text
  51. Can PD-L1 expression be predicted by contrast-enhanced CT in patients with gastric adenocarcinoma? a preliminary retrospective study.2023Abdominal radiology (New York)Free full text
  52. Construction of a nomogram model for predicting peritoneal metastasis in gastric cancer: focused on cardiophrenic angle lymph node features.2023Abdominal radiology (New York)Free full text
  53. M-CSF secreted by gastric cancer cells exacerbates the progression of gastric cancer by increasing the expression of SHP2 in tumor-associated macrophages.2023AgingFree full text
  54. Joint effect of THBS2 and VCAN accelerating the poor prognosis of gastric cancer.2023AgingFree full text
  55. Clinical implications of micro lymph node metastasis for patients with gastric cancer.2023BMC cancerFree full text
  56. Targeting regulatory T cells in gastric cancer: Pathogenesis, immunotherapy, and prognosis.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  57. Effect of sevoflurane on CD4+CD25+FOXP3+ regulatory T cells in patients with gastric cancer undergoing radical surgery.2023Cellular and molecular biology (Noisy-le-Grand, France)
  58. Establishment and validation of a prognostic model for gastric cancer patients of Hebei Province in China.2023Chinese clinical oncology
  59. The inflammatory burden index: A promising prognostic predictor in patients with locally advanced gastric cancer.2023Clinical nutrition (Edinburgh, Scotland)
  60. Mechanisms and biomarkers of immune-related adverse events in gastric cancer.2023European journal of medical researchFree full text
  61. Lymphangiogenesis in gastric cancer: function and mechanism.2023European journal of medical researchFree full text
  62. Prediction of occult peritoneal metastases or positive cytology using CT in gastric cancer.2023European radiology
  63. Comparison of short-term efficacy and safety between total robotic and total 3D laparoscopic distal radical gastrectomy for gastric cancer in Enhanced Recovery After Surgery (ERAS) protocol: a propensity score matching study.2023Journal of robotic surgeryFree full text
  64. Effect of Ward Noise Reduction Technology Combined with Music Therapy on Negative Emotions in Inpatients Undergoing Gastric Cancer Radiotherapy: A Retrospective Study.2023Noise & healthFree full text
  65. Computed tomographic imaging features to differentiate gastric schwannomas from gastrointestinal stromal tumours: a matched case-control study.2023Scientific reportsFree full text
  66. Identification of INHBA as a potential biomarker for gastric cancer through a comprehensive analysis.2023Scientific reportsFree full text
  67. Safety and efficacy of robotic-assisted versus laparoscopic distal gastrectomy after neoadjuvant chemotherapy for advanced gastric cancer.2023Surgical endoscopy
  68. The Regulatory Mechanism and Research Progress of Ferroptosis in Gastric Cancer.2023Technology in cancer research & treatmentFree full text
  69. Computed tomography features of gastric leiomyoma versus gastric stromal tumor: a case-control study with propensity score matching.2023The Journal of international medical researchFree full text
  70. Protein Phosphatase PPM1B Inhibits Gastric Cancer Progression and Serves as a Favorable Prognostic Biomarker.2022Applied immunohistochemistry & molecular morphology : AIMM
  71. Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?2022BMC cancerFree full text
  72. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilim2022BMC gastroenterologyFree full text
  73. LINC01088 regulates the miR-95/LATS2 pathway through the ceRNA mechanism to inhibit the growth, invasion and migration of gastric cancer cells.2022International journal of immunopathology and pharmacologyFree full text
  74. Research on the mechanisms of taraxerol for the treatment of gastric cancer effect based on network pharmacology.2022International journal of immunopathology and pharmacologyFree full text
  75. Assessment of Carbon Nanoparticle Suspension Lymphography-Guided Distal Gastrectomy for Gastric Cancer.2022JAMA network openFree full text
  76. MZF1 Transcriptionally Activated MicroRNA-328-3p Suppresses the Malignancy of Stomach Adenocarcinoma via Inhibiting CD44.2022Journal of immunology researchFree full text
  77. A Nomogram Model for Evaluating the Risk of Lymph Node Metastasis in cT2-cT4N0M0 Gastric Cancer Population.2022Medical science monitor : international medical journal of experimental and clinical researchFree full text
  78. The phosphorylation level of Cofilin-1 is related to the pathological subtypes of gastric cancer.2022MedicineFree full text
  79. Diagnostic accuracy of gastric filling ultrasonography in preoperative invasion depth (T stage) of gastric cancer: Meta-analysis.2022MedicineFree full text
  80. Family history of malignant tumor is a predictor of gastric cancer prognosis: Incorporation into a nomogram.2022MedicineFree full text
  81. To investigate the prognostic factors of stage Ⅰ-Ⅱ gastric cancer based on P53 mutation and tumor budding.2022Pathology, research and practice
  82. Flotillin-1 promotes EMT of gastric cancer via stabilizing Snail.2022PeerJFree full text
  83. Safety and efficacy of carbon nanoparticle suspension injection and indocyanine green tracer-guided lymph node dissection during robotic distal gastrectomy in patients with gastric cancer.2022Surgical endoscopyFree full text
  84. The benefits of surgery plus extensive intraoperative peritoneal lavage (EIPL) for patients with gastric cancer compared with surgery alone: a systematic review and meta-analysis.2022Updates in surgery
  85. Krüppel-like factor 1 serves as a facilitator in gastric cancer progression via activating the Wnt/β-catenin pathway.2021Acta biochimica Polonica
  86. Type I collagen promotes tumor progression of integrin β1 positive gastric cancer through a BCL9L/β-catenin signaling pathway.2021AgingFree full text
  87. Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.2021BMC cancerFree full text
  88. Clinical significance of novel identified high-frequency tumor-specific peptides associated signature in predicting disease status of gastric cancer patients.2021BioFactors (Oxford, England)
  89. Advances in clinical immunotherapy for gastric cancer.2021Biochimica et biophysica acta. Reviews on cancer
  90. 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Metabolic Parameters Before and After Neoadjuvant Chemotherapy Can Predict the Postoperative Prognosis of Locally Advanced Gastric Cancer.2021Cancer biotherapy & radiopharmaceuticals
  91. CDH1 Gene rs1801552 C/T Polymorphism Increases Susceptibility to Esophageal Squamous Cell Carcinoma but Not to Gastric Cardiac Adenocarcinoma.2021Cancer investigation
  92. Role of sympathetic and parasympathetic nerves in the development of gastric cancer through antagonism.2021Chinese medical journalFree full text
  93. Long Non-coding RNA LINC01503 Promotes Gastric Cardia Adenocarcinoma Progression via miR-133a-5p/VIM Axis and EMT Process.2021Digestive diseases and sciences
  94. Up-regulation of KLF17 expression increases the sensitivity of gastric cancer to 5-fluorouracil.2021International journal of immunopathology and pharmacologyFree full text
  95. Meta-analysis of the efficacy of Da Vinci robotic or laparoscopic distal subtotal gastrectomy in patients with gastric cancer.2021MedicineFree full text
  96. Prognostic significance of excision repair cross complementation group 1 rs2298881 in patients with gastric cancer receiving platinum-based chemotherapy: A PRISMA-compliant meta-analysis.2021MedicineFree full text
  97. Circ-sirt1 inhibits growth and invasion of gastric cancer by sponging miR-132-3p/miR-212-3p and upregulating sirt1 expression.2021Neoplasma
  98. TTPAL promotes gastric tumorigenesis by directly targeting NNMT to activate PI3K/AKT signaling.2021OncogeneFree full text
  99. LIMK1 promotes peritoneal metastasis of gastric cancer and is a therapeutic target.2021OncogeneFree full text
  100. Relationship between HER2 expression and tumor interstitial angiogenesis in primary gastric cancer and its effect on prognosis.2021Pathology, research and practice
  101. Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2.2021Scientific reportsFree full text
  102. Research Progress and Application Prospects of Long Noncoding RNAs in Gastric Neoplasms.2021Technology in cancer research & treatmentFree full text
  103. Effect of KLF17 overexpression on epithelial-mesenchymal transition of gastric cancer cells.2021The Journal of international medical researchFree full text
  104. Sevoflurane represses the migration and invasion of gastric cancer cells by regulating forkhead box protein 3.2021The Journal of international medical researchFree full text
Chinese-language papers (not in the count)7
  1. [Cancer burden in Hebei Province from 2011 to 2020].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
  2. [Cancer incidence, mortality and trends among elderly in Hebei province, 2011-2020].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
  3. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled tri2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgeryRCT
  5. [The clinical value of further accurate staging of pT2 gastric cancer based on the depth of invasion].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
  6. [Surgery treatment and prognosis analysis of 129 small cell carcinoma of the esophagogastric junction].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
  7. [The effect of cancer nodules on survival prognosis of gastric cancer patients].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status52
  1. Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)RecruitingNCT07289997Lead sponsorPhase 2Start 2025-09
  2. A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric CancerStatus unknownNCT01836120Lead sponsorPhase 2Start 2013-04
  3. Safety and Efficacy of Ginsenoside Rg3 in Combination With First-line Chemotherapy in Advanced Gastric CancerStatus unknownNCT01757366Lead sponsorPhase 2Start 2012-12
  4. Study Comparing Sequential Therapy of S1+Docetaxel Followed by S1 to Concomitant S1+Docetaxel for Advanced Gastric CancerStatus unknownNCT01718626Lead sponsorPhase 2Start 2012-10
  5. Silent Evaluation of DeepTRG for Assessing Tumor Response After Preoperative Treatment in Stomach and Gastroesophageal Junction CancerRecruitingNCT07849608Lead (inferred)Start 2026-09
  6. DeepComp for Prediction of Gastric Cancer Postoperative Complications (DeepComp-Prospective)RecruitingNCT07401173Lead (inferred)Start 2026-03
  7. Multimodal Deep Learning for Lymph Node Metastasis Prediction and Physician Performance Assessment in T1 Gastric CancerRecruitingNCT07124754Lead (inferred)Start 2025-01
  8. A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10Not yet recruitingNCT07304258Lead (inferred)Phase 2Start 2025-12
  9. AI-Based Prediction of Lymph Node Metastasis in Gastric Cancer Using Preoperative Multimodal DataEnrolling by invitationNCT06957678Lead (inferred)Start 2025-01
  10. Radiomics-Based AI Model for Predicting Para-Aortic Lymph Node Metastasis in Gastric Cancer PatientsEnrolling by invitationNCT06947096Lead (inferred)Start 2025-01
  11. Diagnosis of Peritoneal Exfoliative Cytology-positive Gastric Cancer Based on Artificial Intelligence-driven Virtual Biopsy TechnologyCompletedNCT06759467Lead (inferred)Start 2024-01
  12. Robot-assisted D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric CancersStatus unknownNCT05728606Lead (inferred)N/AStart 2023-01
  13. Multimodal Model Predicts RecurrenceCompletedNCT06690268Lead (inferred)Start 2022-01
  14. Effect of CNSI vs. ICG in Lymph Node Tracing During GastrectomyStatus unknownNCT05229874Lead (inferred)Phase 2Start 2022-01
  15. Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer CellsStatus unknownNCT02510469Lead (inferred)Phase 2/Phase 3Start 2015-07
  16. Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric CancerStatus unknownNCT02509806Lead (inferred)Phase 2/Phase 3Start 2015-07
  17. Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Clinical StudyCompletedNCT02555358Lead (inferred)Phase 2Start 2014-11
  18. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  19. Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)RecruitingNCT07401199Study siteStart 2026-02
  20. Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ AdenocarcinomaNot yet recruitingNCT07902596Study siteStart 2026-10
  21. Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric CancerRecruitingNCT07552402Study siteN/AStart 2026-06
  22. Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric CancerNot yet recruitingNCT07828899Study siteN/AStart 2026-10
  23. Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric CancerRecruitingNCT07127822Study sitePhase 2Start 2025-12
  24. A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ CancerRecruitingNCT07110571Study sitePhase 2Start 2025-08
  25. A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ AdenocarcinomaRecruitingNCT07023315Study sitePhase 3Start 2025-08
  26. A Phase 2 Clinical Study of ABSK061 and ABSK043RecruitingNCT06632262Study sitePhase 2Start 2024-11
  27. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  28. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  29. Exosome-based Liquid Biopsies for Upper Gastrointestinal Cancers DiagnosisStatus unknownNCT06278064Study siteStart 2024-02
  30. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Study sitePhase 3Start 2024-05
  31. Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric JunctionActive, not recruitingNCT06576921Study sitePhase 2Start 2024-11
  32. Plasma Metabolic Biomarkers for Multi-Cancer DiagnosisStatus unknownNCT06363123Study siteStart 2024-03
  33. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  34. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerTerminatedNCT05149807Study sitePhase 2/Phase 3Start 2022-01
  35. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  36. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  37. A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric CarcinomaTerminatedNCT04718402Study sitePhase 1Start 2021-03
  38. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  39. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China ExtensionCompletedNCT04882241Study sitePhase 3Start 2020-07
  40. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  41. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  42. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  43. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  44. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Study sitePhase 2/Phase 3Start 2019-12
  45. A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric CancerStatus unknownNCT04139135Study sitePhase 3Start 2019-12
  46. Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerCompletedNCT04082364Study sitePhase 2/Phase 3Start 2019-09
  47. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Study sitePhase 3Start 2018-11
  48. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedNCT03694522Study sitePhase 2Start 2018-09
  49. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06
  50. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2Status unknownNCT02356276Study sitePhase 3Start 2015-05
  51. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric CancerCompletedNCT01774786Study sitePhase 3Start 2013-06
  52. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Shijiazhuang for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 6 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 2220232024: 0020242025: 112025

8 hospitals in Shijiazhuang for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led6
  1. Oncolytic virus therapy for osteosarcoma: mechanisms, opportunities, and challenges.2025Frontiers in immunology
  2. Machine learning for predicting the survival in osteosarcoma patients: Analysis based on American and Hebei Province cohort.2023Biomolecules & biomedicine
  3. Hub biomarkers in ultrasound-guided bladder cancer and osteosarcoma: Myosin light chain kinase and caldesmon.2023Medicine
  4. Interaction of basic diseases and low red blood cell count as critical murderer of wound infection after osteosarcoma resection: Wound infection after osteosarcoma resection.2022Medicine
  5. Outstanding prognostic value of novel ferroptosis-related genes in chemoresistance osteosarcoma patients.2022Scientific reports
  6. Tumor-associated macrophages in osteosarcoma.2021Journal of Zhejiang University. Science. B
Earlier papers (2016–2020)5
  1. Leptin acts on mesenchymal stem cells to promote chemoresistance in osteosarcoma cells.2020Aging
  2. Association of JMJD2B and Hypoxia-Inducible Factor 1 Expressions with Poor Prognosis in Osteosarcoma.2020Analytical cellular pathology (Amsterdam)
  3. Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma.2019Journal of orthopaedic surgery and research
  4. Expression of Leptin and Sirtuin-1 is associated with poor prognosis in patients with osteosarcoma.2016Pathology, research and practice
  5. The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 7 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.3%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 4420232024: 1120242025: 002025

4 hospitals in Shijiazhuang for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)
Papers it led7
  1. Correlation Between N-Demethyl Imatinib Trough Concentration and Serious Adverse Reactions in Patients with Gastrointestinal Stromal Tumors: A Retrospective Cohort Study.2024Therapeutic drug monitoring
  2. Inflammation and nutritional status indicators as prognostic indicators for patients with locally advanced gastrointestinal stromal tumors treated with neoadjuvant imatinib.2023BMC gastroenterology
  3. A New Online Dynamic Nomogram: Construction and Validation of a Predictive Model for Distant Metastasis Risk and Prognosis in Patients with Gastrointestinal Stromal Tumors.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  4. Computed tomographic imaging features to differentiate gastric schwannomas from gastrointestinal stromal tumours: a matched case-control study.2023Scientific reportsFree full text
  5. Computed tomography features of gastric leiomyoma versus gastric stromal tumor: a case-control study with propensity score matching.2023The Journal of international medical researchFree full text
  6. Effect of skeletal muscle loss during neoadjuvant imatinib therapy on clinical outcomes in patients with locally advanced GIST.2022BMC gastroenterology
  7. Application of radiomics in predicting the preoperative risk stratification of gastric stromal tumors.2022Diagnostic and interventional radiology (Ankara, Turkey)
Chinese-language papers (not in the count)1
  1. [Treatment strategy of gastrointestinal stromal tumors in the background of COVID-19].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
Earlier papers (2016–2020)3
  1. Evaluation for therapeutic measures to small gastric stromal tumor: A retrospective study of 90 cases.2018Current problems in cancer
  2. The risk factors about prognosis of 142 GIST patients with recurrence or metastasis: A retrospective study of single centre in Northern China.2018Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  3. Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China.2017Medicine
All its trials on ClinicalTrials.gov, any status2
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  2. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibCompletedNCT04633122Study sitePhase 2Start 2020-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 4 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 2220242025: 002025

4 hospitals in Shijiazhuang for multiple myeloma178 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis, MRD & risk
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

2 hospitals in Shijiazhuang for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesChildrenEBV & infection triggersGenetics & inherited forms
Departments in papersPediatricsRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 2 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

3 hospitals in Shijiazhuang for myasthenia gravis93 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesThymus & thymectomy

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Shijiazhuang for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

8 hospitals in Shijiazhuang for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

河北医科大学第四医院

Fourth Hospital of Hebei Medical University

石家庄

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Fourth Hospital of Hebei Medical University; Fourth Affiliated Hospital of Hebei Medical University; Hebei Medical University Fourth Affiliated Hospital; Fourth Hospital of Hebei Medical University & Hebei Cancer Hospital; Fourth Hospital of Hebei Medical University Cancer Institute; Tumor Hospital of Hebei

Suggest a correctionDownload the data